This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB03552/identifier/pdb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB03552/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB03552/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/drugbank/drug/DB03552/identifier/drugbank/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB03552
rdf:type
n3:Drug
n3:group
experimental
owl:sameAs
n7:DB03552 n12:DB03552
dcterms:title
Meta-Tyrosine
adms:identifier
n9:46507251 n10:MTY n11:6950578 n13:DB03552
n3:synthesisReference
Franziska Wagner, Johannes Ermert, Heinrich Hubert Coenen, "METHOD FOR PRODUCING PRECURSORS FOR L-2- [18F] FLUOROPHENYLALANINE AND 6- [18F] FLUORO-L--META-TYROSINE AND THE ALPHA-METHYLATED DERIVATIVES THEREOF, PRECURSOR, AND METHOD FOR PRODUCING L-2- [18F] FLUOROPHENYLALANINE AND 6- [18F] FLUORO-L-META-TYROSINE AND THE ALPHA-METHYLATED DERIVATIVES FROM THE PRECURSOR." U.S. Patent US20100256389, issued October 07, 2010.
n3:IUPAC-Name
n4:271B52D3-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B52D9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B52D8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B52D5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B52D6-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B52D7-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B52D1-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B52D2-363D-11E5-9242-09173F13E4C5 n4:271B52CF-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B52D0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B52DF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B52E0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B52DA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B52DB-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B52DD-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B52DC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B52DE-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B52E5-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B52E7-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B52E8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B52E4-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B52E3-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B52E6-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B52D4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B52E1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B52E2-363D-11E5-9242-09173F13E4C5